{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:21:24Z","timestamp":1760646084127},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T00:00:00Z","timestamp":1375920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In a recent clinical trial in kidney transplant recipients, induction with alemtuzumab and rabbit\u2010antithymocyte globulin (r\u2010ATG) was equally effective in preventing rejection during the first post\u2010transplant year; however, this study did not include protocol biopsies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The aim of this study was to analyze the impact of alemtuzumab induction on rejection and subclinical inflammation during the first post\u2010transplant year compared with a historic control group receiving induction with r\u2010ATG. All patients received tacrolimus and mycophenolate mofetil (MMF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 361 in the alemtuzumab group and 478 in the r\u2010ATG groups. Rejection (excluding Banff borderline), during the first year, occurred in 14% of the alemtuzumab group and 9% of the r\u2010ATG group (p\u00a0=\u00a00.03). Estimated glomerular filtration rate (GFR) (chronic kidney disease (CKD)\u2010EPI formula) at one\u00a0yr and graft survival at three\u00a0yr were similar. On the protocol biopsies, interstitial inflammation (Banff i scores) and tubulitis (Banff t scores) were more likely in the r\u2010ATG group at one\u00a0month, but at four and 12\u00a0months, both inflammation and tubulitis were more likely in the alemtuzumab group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We conclude that alemtuzumab induction is associated with delayed inflammation at four and 12\u00a0months, but this inflammation did not appear to negatively impact the GFR or graft survival.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ctr.12201","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T07:03:32Z","timestamp":1375945412000},"page":"772-780","source":"Crossref","is-referenced-by-count":8,"title":["Delayed allograft inflammation following alemtuzumab induction for kidney transplantation"],"prefix":"10.1111","volume":"27","author":[{"given":"Raymond L.","family":"Heilman","sequence":"first","affiliation":[{"name":"Department of Medicine Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan A.","family":"Khamash","sequence":"additional","affiliation":[{"name":"Department of Medicine Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harini A.","family":"Chakkera","sequence":"additional","affiliation":[{"name":"Department of Medicine Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adyr A.","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Surgery Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunam S.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Surgery Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,8]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000281942.97406.89"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01166.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01067.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02273.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31816f60cf"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02492.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31822ca7ca"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000165847.05787.08"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181b4acfb"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009546"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01688.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00299.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02710.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02581.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31818c6db0"},{"key":"e_1_2_5_18_1","first-page":"3","article-title":"Transplant glomerulopathy: subclinical incidence and association with alloantibody","volume":"3","author":"Gloor JM","year":"2007","journal-title":"Am J Transplant"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01836.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01995.x"},{"key":"e_1_2_5_21_1","first-page":"1600","article-title":"B\u2010cell repopulation after alemtuzumab induction\u2010transient increase in transitional B cells and long\u2010term dominance of naive B cells","volume":"2012","author":"Heidt S","year":"2012","journal-title":"Am J Transplant"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02134.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02260.x"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:50:44Z","timestamp":1696402244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/ctr.12201"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12201","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,8]]}}}